Dr. Elsa Abranches joined the UK Stem Cell Bank team in December 2015 as a Senior Stem Cell Biologist. In January 2019, Dr. Elsa was appointed Group Leader of the Section of Stem Cell Biology and Director of the UK Stem Cell Bank.  Her primary focus is developing and delivering a programme of...

My research focuses on tumor immunology, chimeric antigen receptor (CAR) T-cell therapy, and combination immunotherapy for solid tumors. Over the years, our research has yielded mechanistic data that has been translated to CAR T-cell and combination immunotherapy clinical trials for patients with...

Marco is Managing Director of Antion Biosciences and responsible for driving key priorities and developments of the company. After qualifying with his PhD in South Africa, Marco worked for five years in the Biotech and Pharma sectors. During this time, he led the establishment of a novel biomarker...

Professor Emeritus, Dept of General Biology, Faculty of Medicine, University of Patras, Greece.   BSC School of Natural Sciences, University of Athens;  MSc, Genetics, Tel Aviv University and Weizmann Institute of Science, Israel; PhD , Genetics, Imperial College of Science , London, UK. Academic...

Christina Bachmeier is a Clinical Pharmacist in Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida.  She received her Doctor of Pharmacy degree from the University of Florida College of Pharmacy.  After her first-year pharmacy practice residency, she completed a specialized PGY2...

Dr. Stephen Badylak, DVM, PhD, MD is a Professor in the Department of Surgery, and Deputy  Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.  Dr. Badylak has practiced both veterinary and human medicine, and is now fully engaged in research. Dr. Badylak...

Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia.  Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal...

Chip Baird joined bluebird in February of 2019 as chief financial officer. Chip has over 20 years of financial and strategic planning experience in the biopharmaceutical sector. Prior to bluebird, he served as CFO of Amicus Therapeutics for seven years and spent 10 years as CFO of PTC Therapeutics...

Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Sharp & Dohme (MSD). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global...

Dr Richard Beckman was appointed Chief Medical Officer in April 2018. Prior to joining ReNeuron, Dr Beckman was the Chief Medical Officer of several innovative biotech and device firms, including Clearside, Ophthotech and Neurotech. Prior to that, he had leadership roles at Alcon, Lux Bio, Becton...

Buzz Bies is a graduate of the University of New Hampshire.   He has been part of MVE’s cryogenic businesses since 1985 and has had Cryo-biological specific responsibilities in a Vice President role since 2010.  Buzz assisted in the editing of ISBER’s Cold Storage Best Practices and participates...

Axel Boehnke is Director Market Access. He´s fully responsible all market access aspects, patient access as well early evidence planning as well as actions to accelerate access to patients, currently with the focus on orphan diseases and gene therapy. His experience in this area of work has allowed ...

I am a pediatric hematologic oncologist and Chief of the Pediatric Stem Cell Transplantation and Cellular Therapies Service. I specialize in bone marrow and cord blood transplantation to treat blood diseases in children and young adults. I have particular expertise in treating rare diseases, such...

PhD in Life sciences in 2015 on Stem cell biology and Genome-wide studies on remodeling factor followed by a business degree in Pharmaceutical and Biotechnology Management (2017). Current position as a Business Development Officer at Genethon since September 2017.

Philip John (P.J.) Brooks is a Program Director in the NCATS Office of Rare Diseases Research (ORDR). Dr. Brooks received his Ph.D. in neurobiology from the University of North Carolina at Chapel Hill. After completing a postdoctoral fellowship at the Rockefeller University, Brooks became an...

Heather Callahan joined the Gates Center for Regenerative Medicine as Director of Business Services in 2013, initially focused on developing the intellectual property portfolio. In 2017, she began to share her time with CU Innovations and became an Entrepreneur in Residence focused on developing...

Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics (NASDAQ: FOLD) and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization...

Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and PhD in (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation in, Biochemical Engineering (1991), NOVA-Univ. Nova de Lisboa. Full Professor, Chemical and Biochemical...

Mark Chalmers is a Partner in the EY Life Sciences Commercial Access team, with more than 15 years of experience specialising in global commercial and launch strategy, including international pricing and market access for pharmaceutical and biotech companies. He has global experience of healthcare...

Guoling has over 10 years experience in health care and, research, in both academia and industry settings, 7 years of which are in cell therapy product manufacturing and quality aspects, including both minimally-manipulated and more-than-minimally-manipulated cell therapy products. Guoling is...

Lung-I Cheng, PhD, is Head of Global Value & Access, Cell Therapies at Takeda Pharmaceuticals. In this role, he leads the access strategy for Takeda's portfolio of cell therapy assets in oncology. Prior to this, he oversaw the market access efforts for the company's lymphoma...

Maria brings extensive technical expertise in the biologic therapeutics, cosmetics and CRO/CMO industry to Dendreon. With more than 15 years combined sales/technical/operations experience in both commodities and outsourced manufacturing services, Maria is responsible for accelerating Dendreon’s...

The Paul-Ehrlich-Institut is a research and science driven Medicines Agency (veterinary and human vaccines, human biomedicines) reporting to the German Federal Ministry of Health and providing regulatory services to the European Medicines Agency EMA, EDQM, WHO and others.Professional career:  1976...

Francesco Cicirello is Associate Director (Site Quality Head) at Adaptimmune in the United Kingdom. Before joining Adaptimmune, Francesco worked in a Regulatory Agency. He was an Expert Inspector at the Therapeutic Good Administration (TGA) in Australia. He was elected to several roles in PIC/S...

Angela Columbano has over 20 year experience in the pharmaceutical and Biomedical industry. Prior to Genethon, Angela was Principal at Sanofi Sunrise an early investment and partnering vehicle. Angela has also held various positions with Sanofi in Marketing and Business Development and Licensing...

Jean-Philippe has 28 years of experience in the pharma & biotech industries. He is a highly skilled senior executive with a broad range of experience leading global development and a successful track record of partnership, innovation and development in the area of Orphan Drugs. Co-Founder of...

Prior to joining Tmunity, Dr. Coughlin was Chief Medical Officer at British biotechnology company, Immunocore Ltd., where she was responsible for leading the effort to develop novel bispecific T cell receptor-based biologics for cancer immunotherapy. Dr. Coughlin led the clinical efforts and...

Doug has more than 18 years of Pricing & Market Access experience including roles with Eli Lilly & Company, AMGEN, Millennium/Takeda Oncology and now bluebird bio. In that time, he has led or overseen the preparation of market access strategies for products in early development, pivotal...

Eric Michael David is CEO of gene therapy at BridgeBio. He was a co-founder of Organovo, where he most recently served as Chief Strategy Officer and Executive Vice President of Preclinical Development. Prior to Organovo, Dr. David was an Associate Partner at McKinsey & Co, where he served...

Freddie is a Partner on the Life Sciences team at Syncona. He has been involved in a number of Syncona?s investments, most notably Quell Therapeutics where he spent a year as Director of Operations and is an Observer on the Board of Directors. Previously, he was a member of the Investment Team at...

I am aa RN with over 15 years of experience, the last 6 of which have been a clinical trial nurse. I work in the Cellular Therapeutics Center, where we treat patients with Immune Effector Cells on Phase I/II trials. My primary responsibilities include collaborating with physicians and research team ...

MedNous is a business-science publication about managing innovation in the life sciences. It is owned by Evernow Publishing Ltd, a family-run business, and targeted at a professional audience consisting of academics, entrepreneurs, financial intermediaries, government regulators, service providers...

Dr Michael Ermisch is a pharmacist by training who specialised in drug information. His doctoral thesis dealt with the regulation of nuclear receptors. Since 2013, he has been a specialist consultant in the Department of Drugs and Remedies of the GKV-Spitzenverband with various thematic...

Dr. Fan is the co-founder of Legend Biotech and currently serves the company as the Chief Scientific Officer. Dr. Fan received his medical degree at Xi?an Jiaotong University in 1993 and worked as a surgical resident in the kidney Transplantation Centre of the university before he pursued his...

Suzanne Farid is Professor of Bioprocess Systems Engineering in the UCL Department of Biochemical Engineering and Deputy Head of Department (Education). She is a Fellow of Institution of Chemical Engineers (FIChemE).  She sits on the UK BioIndustry Association Manufacturing Advisory Committee and ...

Mike Fraser is General Manager of Europe, Middle East and Africa for Novartis Gene Therapies. In this role, Mike is leading a team that will introduce innovative Gene Therapies to the market to help babies and their families who suffer from rare neuromuscular diseases. Previously, Mike led Sandoz? ...

Michela Gabaldo is Head, Alliance Management & Regulatory Affairs at Fondazione Telethon in Milan, Italy where she joined in 2011. As Head of Alliance Managment she was responsible for the execution of the first strategic Alliance of Telethon/OSR with GSK managing gene therapy projects at...

Joe Garrity is the Head of Autologous Cell Therapy, Commercial Development at Lonza Cell and Gene Technologies where he works within their global Cell and Gene business unit. He works within the business leadership team to enable strategic development and growth of the autologous modality in Lonza...

Dr Getts is co-founder and CEO, of  Myeloid Therapeutics. Prior to Myeloid, he was VP of Research at TCR2 (NASDAQ, TCRR), he was a member of the leadership team that guided the company successfully through a series B ($120M) financing and an IPO (~$80M). Dr Getts primary duties were to lead the...

Dr. David Gilham is Vice-President R&D of Celyad. He heads the implementation of Research and Development strategy for the immune-oncology programs. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T...

As EY Global Life Sciences Digital, Social and Commercial Innovation Leader, Adlai is focused on developing the necessary digital infrastructure to support emerging, next-generation forms of individualized therapies to tackle cancer and rare diseases.Adlai is the solutions leader for...

After almost eight years at Goldman Sachs JBWere in Australia, Simon completed a neuroscience PhD and postdoc in Cambridge, and worked for several years in the UK biotech startup sector. He brings deep and diverse skills to management of life-science investing for the UCL Technology Fund. ?It?s...

Ian Goodwin is Associate Director in the Global Program Design team at FUJIFILM Diosynth Biotechnology (FDB), based in College Station, Texas. He has been at FDB for three years, having also served as Associate Principal Scientist in the Process Development group. Ian is currently responsible for...

Cecilia Götherström is an Associate Professor in Stem Cell Research at Karolinska Institutet in Sweden and her research is in the field of perinatal regenerative medicine. Dr Götherström has developed fetal mesenchymal stem cells for prenatal and postnatal transplantation purposes and since then...

Miriam Haak, Director Business Development at Miltenyi Biotec GmbH, is responsible for the evaluation and establishment of partnership programs in the context of Miltenyi Biotec?s lentiviral vector and cell manufacturing services. She worked as an immunologist at the Max-Planck-Institute for...

Hansjörg Hauser?s expertise is molecular biology. He is studying events in transcription activation and signal transduction that mediate consequences of infections. With this work he tries to connect molecular events of innate immune reactions with complex phenotypes in the organism. He is also...

Amir Hefni is Vice President and Global Commercial Head for Cell & Gene, having joined Novartis in May 2020. He leads the global commercialisation of Cell & Gene therapies for Novartis Oncology.  Amir joined Novartis from Ipsen, where he was Oncology Brand Global General Manager and led the ...

Luke serves as Vice President Operations & Corporate Development where is responsible for portfolio strategy, corporate/business development, business operations, and legal functions. He joined Quell from Neon Therapeutics where he served as Senior Director of Business Development &...

Christoph Herwig, bioprocess engineer from RWTH Aachen, worked in industry in the design and commissioning of large chemical facilities prior to enter his interdisciplinary PhD studies at EPFL, Switzerland in bioprocess identification. Subsequently he positioned himself at the interface between...

Reinout is an effective professional in the field of cell and gene therapies manufacturing, with over 17 years of experience and an emphasis on CMC, product development and quality. As a consultant he has focussed on the development of cell and gene therapies and their production process from early ...

Emily Hopewell began her career at the Moffitt Cancer Center as a technologist in the Cell Therapy Facility in 2003. She received her PhD in Cancer Biology from the University of South Florida and returned to the Cell Therapy Facility as a Development Specialist and then Assistant Technical...

Dr. Moshe Israeli serves as the director of the tissue typing laboratory of the Beilinson Hospital, Rabin Medical Center in Israel. In his clinical duty Dr. Israeli is responsible for all immuno-genetic diagnostic testing of all organ and stem cell transplants carried out by the Clalit Health...

Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different...

Steve is the Chief Scientific Officer of Caribou Biosciences responsible for R&D activities related to therapeutic discovery and development.  Before joining Caribou, Steve served in positons of increasing responsibility in both oncology and immunology/inflammation drug discovery at...

Cornelia Kasper studied Chemistry at the University Hannover and received her Diploma degree 1994. She performed her dissertation at the Institute for Technical Chemistry 1995-1998 and graduated as Dr. rer. nat.. Until 2000 she was employed as EU liason officer at the University of...

Aisha has twenty years of professional experience in medical, manufacturing, quality assurance, regulatory, and service related environments. While working at the University of Miami?s GMP facility, she has setup and managed many national and international state of the art research facilities. She...

Dr. Sebastian Kress is a postdoctoral scientist at the Institute of Cell and Tissue Culture Technologies at BOKU, Vienna, Austria. His research focuses on non-destructive online monitoring of metabolic parameters and the secretome of 3D cell cultures combining dynamic cultivation systems and...

Dr. Joanne Kurtzberg is an internationally renowned expert in pediatric hematology/oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and novel applications of cord blood in the emerging fields of cellular therapies and regenerative...

Dr. Lamb is scientific co-founder, Executive Vice President, and Chief Scientific Officer of Incysus Therapeutics.  As a transplant immunologist with 27 years? experience in clinical-translational immunotherapy research, he is responsible for first describing the association between relapse-free...

In his current role at Brooks, David visits with leading research, manufacturing and patient care facilities who require cryogenic infrastructure to support their efforts.  He recently completed his elected term as President for the International Society of Biological and Environmental Repositories ...

Nick Li is currently senior director and head of health economics and outcomes research at uniQure, a leading gene therapy company. Nick is a value and access leader in building global HEOR functions, integrating HEOR into development and commercialization process, optimizing product value...

Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also chief...

Rey joined Accellix as its Vice President Sales and Marketing in July 2019. She has served as a Product Development and Marketing leader for the prior 14 years in both hi-tech and biotech companies. Rey has a graduate degree in Medical Research and a MBA from The University of California, Berkeley...

Christopher has a PhD in Biochemistry (Molecular biology) in gene therapy for muscular dystrophy. He has been an academic researcher in gene therapy, muscle regeneration and muscular dystrophy as well as diabetes for 15 year and has published numerous original research papers and review articles...

Peter Marks, M.D., Ph.D. is the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and ...

I am currently a Review Director at the Office of Cellular and Tissue-based Products at the Pharmaceuticals and Medical Devices Agency (PMDA), Japan. In 2008, I joined PMDA as an officer in the Office of Compliance and Standards where I was also a secretariat for the Japanese Pharmacopoeia till...

Allison Matthews is a lead service designer at the Mayo Clinic Kern Center for the Science of Health Care Delivery: Innovation and Design in Rochester, Minnesota where she utilizes her experience in health care along with her design training to innovate around the delivery and experience of health...

David J. Mazzo, PhD, was appointed as Caladrius' Chief Executive Officer and as a member of our Board of Directors on January 5, 2015. In addition, Dr. Mazzo was appointed as President of the Company in March 2017. Dr. Mazzo brings to the Company over 35 years of international experience in the ...

Joe Garrity is the Head of Autologous Cell Therapy, Commercial Development at Lonza Cell and Gene Technologies where he works within their global Cell and Gene business unit. He works within the business leadership team to enable strategic development and growth of the autologous modality in Lonza...

Sarah has over 20 years of senior-level management experience in corporate development in the advanced therapies sector. She is currently Vice President of Business Development, Life Sciences at MaxCyte, Inc. Previously, she was the Vice President of Business Development for Synpromics Ltd. from...

Leslie Meltzer, PhD, is an award-winning Medical Affairs leader with proven track record of strategic and operational success across broad range of functions (Medical Director, Medical Information, MSL Training, Medical Communications, Phase IV research, KOL engagement/advisory board management)...

Dr. Federico Mingozzi is the chief scientific officer at Spark Therapeutics, bringing two decades of experience in gene therapy, immunology, as well as biochemistry and molecular biology in both industry and academic settings. Federico began his scientific career studying the genetic basis of...

Félix, is a Scientific Director of the Healthcare Business of bioMérieux. Félix has over 25 years of experience in industrial and clinical diagnostics and previously served as the Chemunex R&D Director in bioMérieux. Félix graduated from the Autonomous Metropolitan University in Mexico as...

Paolo is a healthcare investment and market access professional with more than 15 years of experience in both assessing and supporting access to innovative healthcare technologies. Since 2017, Paolo is EU Director Market Access and Members Relations at the Alliance for Regenerative Medicine (ARM)...

Snehal brings a confluence of early discovery, innovation and scientific expertise to her hybrid role as Spark?s Regulatory Policy Leader and Regulatory Strategy Leader for ocular programs. In this capacity she is establishing the regulatory policy function at Spark and supporting global...

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law...

Dr. Steve Oh obtained his PhD from Birmingham University, UK (1990) and is the Director of Stem Cell Bioprocessing and Institute Scientist, Stem Cell Group. He has had several industry leadership roles e.g. Asia-Pacific Vice President of International Society of Cell and Gene Therapy (ISCT); Member ...

Daniel O?Mahony is a Partner at Seroba Life Sciences and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation. Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He...

Nneka C. Onwudiwe, PhD, PharmD, MBA received her doctorate in Pharmacy (PharmD) from the University of Maryland School of Pharmacy, PhD in Health Services Research with a specialization in Pharmacoeconomics from the University of Maryland School of Pharmacy, and an MBA (Honors) from the University...

David Morrow is Programme Manager Translational Medicine & Drug Development at EATRIS. David received a BSc (Hons) in Molecular Biology from University College Dublin in 2001 and a PhD in Vascular Biology from Dublin City University in 2006. This was followed by an American Heart Association...

Since January 2017 Dr. Detlev Parow is Head of the Department of Medicines, Therapeutic Appliances and Remedies at DAK-Gesundheit in Hamburg. From 2010 to 2016 he was responsible for Care Management Development at DAK-G. From 2002 to 2009, he worked for Hamburg Münchener, initially leading the...

C. David Pauza, PhD is Chief Science Officer for American Gene Technologies and former Professor of Medicine at the University of Maryland Medical School in Baltimore. Prior to joining AGT, Dr. Pauza was Associate Director for the university?s prestigious Institute of Human Virology and Co-Leader...

Dr Qasim Rafiq is a Senior Lecturer (Associate Professor) in Cell & Gene Therapy Bioprocessing within the Department of Biochemical Engineering at University College London (UCL).   Prior to this he was a Lecturer (Assistant Professor) in Bioprocess Engineering at Aston Medical Research...

Vardit Ravitsky is Full Professor at the Bioethics Program, School of Public Health, University of Montreal and part-time Senior Lecturer on Global Health and Social Medicine at Harvard Medical School. She is President of the International Association of Bioethics and Director of Ethics and Health...

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development in charge on process & technology development and manufacturing sciences. Prior to that Mr. Raviv served as Projects manager & Product development Team leader at Pluristem in charge of new technologies ...

Al Ribickas is the BMT/QC Laboratories Manager in the Cell Therapies Facility at the Moffitt Cancer in Tampa Florida.  Al has provided leadership for cellular therapy facilities for over eighteen years. He attended the University of South Florida receiving a degree in Clinical Laboratory...

Vincent Rotello is the Charles A. Goessmann Professor of Chemistry and a University Distinguished Professor at the University of Massachusetts at Amherst. He received his B.S. in Chemistry in 1985 from Illinois Institute of Technology, and his Ph. D. in 1990 in Chemistry from Yale University. He...

The emphasis of Dr.Russ`s research is on understanding the underlying molecular and cellular mechanisms resulting in autoimmune type 1 diabetes (T1D) in humans, with a focus on the insulin-producing beta cells. During his career, Dr. Russ successfully worked on different aspects of T1D, which led...

Marika Russo, PhD, is Market Access Director at Novartis Gene Therapies (former AveXis) Italy and Greece with a key focus on the price and reimbursement process for Zolgensma, the first gene replacement therapy in SMA. Her expertise ranges from market access strategy, evidence generation and value...

Mark Sawicki brings 15 years of business development and sales management experience, having consistently delivered on corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Sawicki was most recently the chief business officer at AAIPharma Services...

David Schaffer is the Hubbard Howe Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at the University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He received a B.S. from Stanford University in 1993 and a...

Dominic is a Partner of Syncona. Prior to joining Syncona, he worked in the life sciences team of strategy consultancy L.E.K. Consulting. Dominic received his PhD from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom ...

As of May 2018, Orlando leads the program strategy for the recently announced  Chimeric Antigen Receptor T-Cells therapeutic area.  This includes digital  strategies, supply chain network design, and supply chain capability  development for this therapy platform, currently targeted as a last line...

Tamir has a background in management consulting with an MBA prior to taking different roles in the NHS, both working for a Trust and a Commissioner, as well as working for an international acute hospital chain. Tamir joined NHS England in 2016 and he is now the Head of Commercial Development in the ...

Devyn joined Sigilon Therapeutics in early 2017 as Chief Strategy Officer and Head of Operations. In this role, he has led the development of the corporate strategy, portfolio strategy and other key strategy elements.  In addition, he is accountable for project management, intellectual...

Dr. Stavas leads the strategic advancement of clinical trials and scientific discovery and development at inRegen. He has over 30 years of experience in medical practice, academics and research endeavors and been affiliated with inRegen since 2012. He serves as liaison between consultants, clinical ...

Dick Sundh is Vice President, Marketing and Head of Australia, Canada and Europe (ACE) at Kite, a Gilead Company. In his role, Mr Sundh oversees European commercial operations for Kite's growing portfolio of cell therapies.  Mr Sundh has more than 17 years' experience in international...

Mark D Swartz, M.B.A., M.Ed., is helping raise awareness about potential Down Syndrome extinction. He is a Canadian author of best-selling non-fiction, and former columnist with a leading North American newspaper. Currently he is writing a provocative debut novel that explores the medical...

Hardy TS Kagimoto, MD is founder, Chairman and CEO of HEALIOS K.K., a Tokyo-based, clinical-stage world leader in regenerative medicine and cell therapy.After founding Healios in 2011, Dr. Kagimoto led the company’s listing on the Tokyo Stock Exchange in 2015 and has built the company to its...

Dr Aristides Tagalakis is a Reader in Gene Delivery and Nanomedicine at Edge Hill University. The main objective of his current research has been to develop and evaluate different non-viral and nanoparticle technologies in gene therapy for cancer, cystic fibrosis, glaucoma and cardiovascular...

Dr. Tai graduated from UC Berkeley (BA, Molecular and Cellular Biology), and University of Washington (PhD, Biochemistry). He is currently an Assistant Professor at the University of Massachusetts Medical School in the Horae Gene Therapy Center and Department of Microbiology and Physiological...

Dr. Tarunina joined Plasticell Ltd as Principal Scientist in 2007 and become company?s Research Director in 2017. She has contributed to the development of the company?s CombiCult® technology platform and exemplified its broad applications in different areas of stem cell biology. Prior to joining...

Dr. Hartmut Tintrup is the Global Head of Business Development & Partnering activities for Lonza’s Cell & Gene Technologies Business Unit. He started at Lonza in 2017 with the responsibility of Business Development & Partnering Activities for the EMEA region. Dr. Tintrup has more than...

Ariette Van Strien, President, offers 28 years of clinical research experience from Phase I to Phase IV and has held senior executive roles across global marketing and business development, pricing as well as project management and global operations functions. Ariette’s ability to lead global teams ...

R & D+i Director of the Biology Area Servicio de Medicina de la Reproducción de Dexeus Mujer (2005) Director of Barcelona Stem Cell Bank. Instituto de Investigación Biomédica de Bellvitge (IDIBELL) (2005? ) Associate Professor of Departament Ciències de la Salut i de la Vida, Universitat Pompeu ...

Dr David Venables is President, AskBio Europe, following the acquisition of Synpromics Ltd, where he was CEO. AskBio is a world leading gene therapy company with unrivaled technology and a promising therapeutic pipeline. As CEO of Synpromics, he led the growth of the company through a strategic...

Gary resides in England and is fueling Stirling Ultracold’s global growth in the United Kingdom and in Nordic countries. Gary brings 25 years’ experience of sample storage solutions in pharma, biotech and life sciences markets. He has deep industry knowledge of drug discovery, biobanking, clinical...

Phil Wilson is an accomplished supply chain executive with over 25 years of industry experience. Prior to joining Cryoport, Phil served as Vice President, Supply Chain for Ancillare LP and before that, as the Director of Global Operational Programs at Catalent Pharma Solutions, where he managed all ...

Tom Wilton currently serves as the Chief Business Officer for Carisma Therapeutics. He has over 20 years of pharmaceutical and biotechnology industry experience, including corporate strategy, business development, R&D operations and marketing. Tom most recently served as the Chief Business...

Jie Zhang is the Head of Global Value & Access in Cell & Gene unit at Novartis Oncology. In his role, he led the development of HEOR, market access and pricing strategy for multiple disease areas including launches of Kymriah, Tafinlar/Mekinist combination, Zykadia, and Afinitor. In...